Research

Breadcrumb trail

Need Help or want to give your feedback?

Whether you’re having trouble with your account, or would like to make a suggestion, Canadian Blood Services offers you quick and convenient options to troubleshoot or get in touch. Contact us via live chat, consult our FAQ, send an email feedback@blood.ca, or give us a call at 1 888 2 DONATE (1-888-236-6283).

Investigating the mechanism of anti-CD44 antibody amelioration of IVIg-treatable disease

Principal Investigator / Supervisor: 
LAZARUS, Alan
Co-Investigator(s) / Trainee: 
NORRIS, Peter
Institution: 
University of Toronto
Province: 
Ontario
Project Start Date: 
April 1, 2017
Project End Date: 
March 31, 2019
Summary: 
The intravenous injection of blood serum immunoglobulins (IVIg) is an important medical treatment for many diseases. IVIg is acquired by combining serum antibodies from potentially thousands of blood donors. However, IVIg has several clinical challenges, including high cost, destruction of recipient red blood cells, and theoretical risk of infectious disease transmission. Our laboratory is investigating a new therapeutic called anti-CD44 to replace IVIg. This therapeutic is able to treat many of the same diseases as IVIg. However, it is unclear how anti-CD44 works so many different diseases. We will first investigate anti-CD44 in Immune Thrombocytopenia, where cells called macrophages destroy platelets through a celleating process known as phagocytosis. We will first test how anti-CD44 prevents platelet destruction by determining which step of macrophage phagocytosis becomes blocked. We will also investigate if the signaling within macrophages required to complete phagocytosis has changed following treatment with anti-CD44. We will then use knowledge generated from our research in immune thrombocytopenia to help determine how anti-CD44 works in other inflammatory diseases such as rheumatoid arthritis that are IVIg-treatable. This research will help ensure an affordable and accessible supply of IVIg to Canadians by providing a novel, alternative therapeutic for IVIg-treatable diseases.
Total Amount Awarded: 
$52,000
Program: 
Graduate Fellowship Program

Projects summaries are contributed by investigators who receive financial support from Canadian Blood Services. The summaries are intended to inform the public of the types of research projects that are supported by our organization. The information described in project summaries should not be considered as recommendation for clinical treatment and diagnosis.